Repare Therapeutics Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Repare Therapeutics Inc. | RPTX - NASDAQ |
$16.00-$18.00 | $20.00 | $32.05 | 11 million | 6/19/2020 |
| Morgan Stanley, Goldman Sachs, Cowen, Piper Sandler | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Amended Terms 2020-06-17 Filed 2020-05-29 Terms Added 2020-06-15 | ||||||
Repare Therapeutics Inc. Quote & Chart - Click for current quote - RPTX
IPO Boutique aggregates information on public companies and private companies, such as "RPTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Repare Therapeutics Inc. (adapted from Repare Therapeutics Inc. prospectus):
They are a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a leading precision oncology company enabled by our proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Synthetic lethality, or SL, represents a clinically validated approach to drug development.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "RPTX" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.